- For Patients
- Introduction to the Marshall Protocol
-
Length of the MP - Immunopathology
- Managing Immunopathology
- Food and Drink
- Light Restriction
- Suitability of the Marshall Protocol
- Starting the Marshall Protocol
- Working with a Physician
- Phase One Guidelines
- Phase Two/Three Guidelines
- Palliative vs. Curative Treatments
- Patient Interviews on Bacteriality
- Non-MP Treatments
- Glossary
- For Physicians
- Publications and Presentations
- Science Behind Marshall Protocol
- Science Behind Immunopathology
- Science Behind Olmesartan (Benicar)
- Safety of Olmesartan (Benicar)
- Safety of MP Antibiotics
- Phase One Guidelines
- Phase Two/Three Guidelines
- Suitability of the Marshall Protocol
- Physicians' Concerns About the MP
- Notice for Emergency Medical Personnel
- For Researchers
- Publications and Presentations
- Science Behind Marshall Pathogenesis
- Science Behind Vitamin D
- Molecular Activity of Vitamin D and the VDR in Chronic Disease
- Th1 Spectrum Disorder – how chronic inflammatory diseases are related
- Transmission of Bacteria and Onset of Chronic Disease
- Pea Soup, Successive Infection, and Variability in Disease
- Evolutionary Perspective on Chronic Disease
- Incidence and Prevalence of Chronic Disease
- Evidence that Chronic Disease Is Caused by Pathogens
- Diseases
- About ARF
- Related Sites
Rheumatoid arthritis
Treatment of early seropositive rheumatoid arthritis with minocyclineBacteriostatic antibiotic used by Marshall Protocol patients.: four-year followup of a double-blind, placebo-controlled trial.
O'Dell JR, Paulsen G, Haire CE, Blakely K, Palmer W, Wees S, Eckhoff PJ, Klassen LW, Churchill M, Doud D, Weaver A, Moore GF. Department of Internal Medicine, University of Nebraska Medical Center, Omaha 68198-3025, USA. OBJECTIVE: Rheumatoid arthritis (RA) causes substantial morbidity and mortality, and current treatments are suboptimal. Recent studies have demonstrated the short-term efficacy of minocycline in the treatment of patients with early RA. This study was undertaken to compare patients treated with conventional therapy in the early phase of their RA and those treated with minocycline, after 4 years of followup. METHODS: Forty-six patients with seropositive RA of <1 year's duration had been enrolled in a double-blind study of minocycline (100 mg twice daily) versus placebo. After the blinded portion of the study (3-6 months, depending upon response), all patients were treated with conventional therapy. This report compares those patients randomized to receive placebo for 3 months and then conventional therapy for the duration of 4 years versus those originally randomized to receive minocycline. RESULTS: Twenty of the 23 original minocycline-treated patients and 18 of the 23 original placebo-treated patients were available for followup (mean 4 years). At followup, RA was in remission (American College of Rheumatology criteria) without disease-modifying antirheumatic drug (DMARD) or steroid therapy in 8 of the patients originally treated with minocycline compared with 1 patient in the placebo group (P = 0.02). Ten patients in the minocycline group versus 16 in the original placebo group currently require DMARD therapy (P = 0.02). CONCLUSION: Among patients with seropositive RA, remissions are more frequent and the need for DMARD therapy is less in those treated early in the disease course with minocycline compared with those treated with conventional therapy delayed by an average of only 3 months. Minocycline appears to be an effective therapy for early RA; further investigation into its mechanism of action is needed. PMID: 10446869
Evidence of infectious cause
Sample PubMed cite1)
Notes and comments
f17:
Rheumatic diseases
Our Autoimmunity Reviews paper specifically identifies rheumatoid arthritis, systemic lupus erythematosus, and Parkinson's as Th1 diseases. http://dx.doi.org/10.1016/j.autrev.2003.10.001
Fulltext preprint is at http://yarcrip.com/sarcoidosissuccumbs-preprint.htm
Lupus In 'Overlap' With Other Connective Tissue Diseases
Nothing contained in this site is or should be considered, or used as a substitute for, medical advice, diagnosis or treatment by your physician.
- f17
s254:
Death risk linked to steroid use for arthritis (filelink) “Patients with rheumatoid arthritis who are treated with low-dose steroids for more than 10 years are more likely to die than patients who are less exposed to these drugs ”
Barb: Dx Inflammatory Disease Endocrine Imbalance 2003| 24+ years not Dx| MP Aug04|
- s254
s250:
Personal Experience:
marion villa this is a piece of cake my friends… and I am heading for a completely healthy life.
Michele MBK: RA: boost in confidence in resuming life-activities while on MP
John McDonald: RA: Road Back and MP story. other unexpected gains.
Interview with Ival Meyer - arthritis, dyslexia
davbrkr Dave: Lyme 40+ yrs: RA: 1 month-17 days on Phase I
Christina JRA MP summary
Ival RA: MP is the right treatment for RA
Christina: RA - First Anniversary update
Carol: new RA update Phase three
Ival: RA: update: gone back to work. MP 21 months.
Christina: RA - re should I wait to MP?
Carol: RA - MP personal experience
Ival can you work on MP?
Christina RA: food sensitivities lessening. very active. recovering more quickly. Christina re JRA: personal experience.
Ival: RA: my most active month ever since starting the MP.
Help from RA members
John McDonald: RA: My RA “remission” is more secure now
Ival: RA: Here is my little speech I gave at the Los Angeles conference. see DVDs. Ival: RA: I've got my life back Ival: RA improvements..8 months … 1 year….
Has anyone had evidence of joint improvement? Carol RA: summary Carol RA: off thyroid meds
Christina RA personal experience
AmyEliz: RA: my 'positives'…. RA: summary
See also
PAIN CONTROL
see Standard Treatments information link and scroll down
Last edited on Mon Aug 11th, 2008 00:15 by
- s250
